38
Participants
Start Date
April 7, 2021
Primary Completion Date
July 30, 2024
Study Completion Date
July 30, 2024
Sintilimab
Sintilimab 200mg iv. q3w, up to 2 years.
Bevacizumab Biosimilar IBI305
Bevacizumab 15mg/kg iv. q3w, up to 22 cycles
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Union Hospital affiliated to Tongji Medical College
UNKNOWN
Qilu Hospital of Shandong University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Henan Cancer Hospital
OTHER_GOV
Hubei Cancer Hospital
OTHER
Shengjing Hospital
OTHER
Anhui Provincial Cancer Hospital
OTHER
Zhongnan Hospital
OTHER
Jingzhou Central Hospital
OTHER
The First People's Hospital of Jingzhou
OTHER
Xiangyang Central Hospital
OTHER
Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital
UNKNOWN
Tongji Hospital
OTHER